The discovery of programmed cell death 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein-4 (CTLA-4) has promoted the development of tumor immunotherapy. Here, PDCD1 is linked to neoplasm.